Why has polio eradication program failed in India?

Indian Pediatrics

Volumn 45, Issue 5, 2008, Pages 381-388

  Paul, Yash ^a,b  

^a Maharaja Agrasen Hospital   (India)

^b Bani Park ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; DEVELOPING COUNTRY; DRUG SAFETY; FLACCID PARALYSIS; HEALTH PROGRAM; HEALTH SURVEY; HEPATITIS B; HERD IMMUNITY; HEREDITY; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; INDIA; MALNUTRITION; MEASLES; MIXED INFECTION; MORBIDITY; POLIOMYELITIS; POLIOMYELITIS VIRUS 1; REVIEW; TREATMENT RESPONSE; VACCINE FAILURE; VIRUS IMMUNITY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

CHILD, PRESCHOOL; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; INCIDENCE; INDIA; INFANT; INFANT, NEWBORN; MASS IMMUNIZATION; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL;

EID: 44349151016     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Mittal SK, Mathews JL. Polio eradication in India: the way forward. Indian J Pediatr 2007; 74: 153-160.
2. Polio Eradication Strategies in India: Recommendations under IAP Action Plan 2006. Indian Pediatr 2006; 43: 1057-1063.
3. Paul Y. Role of genetic factors in polio eradication: New challenge for policy makers. Vaccine 2007; 25: 8365-8371.
4. Park K. Park's Textbook of Preventive and Social Medicine, 18th ed. Jabalpur: Banarsidas Bhanot; 2005. p. 164-165.
5. Singhal T, Amdekar YK. IPV-Doubts persist (Reply). Indian Pediatr 2007; 44: 711-712.
6. Chen RT, Hausinger S, Dajani AS, Hanfling M, Baughman AL, Pallansch MA, et al. Seroprevalence of antibody against poliovirus in inner city preschool children. JAMA 1996; 275: 1639-1645.
7. Minor PD. The molecular biology of polio vaccines. J Gen Virol 1992; 73: 3065-3077.
8. Melnick JL. Combined use of live and killed vaccines to control poliomyelitis in tropical areas. Reassessment of inactivated poliomyelitis vaccine. Vaccine 1981; 1: 265-273.
9. Kohler KA, Bannerjee K, Hlady WG, Andrus JK, Sutter RW. Vaccine associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull WHO 2002; 80: 210-216.
10. Paul Y. Herd immunity and herd protection. Vaccine 2004; 22: 301-302.
11. Paul Y. What needs to be done for polio eradication in India? Vaccine 2007; 25: 6431-6436.
12. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992; 14: 568-579.
13. Nkowane BM, Wassilak SGF, Orenstein WA, Bart KJ, Schonberger LB, Hinman AR, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 1987; 257: 1335-1340.
14. Andrus JK, Strebel PM, de Quadros CA, Olive JM. Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-1. Bull WHO 1995; 73: 33-40.
15. Paul Y. Accuracy of the National Polio Surveillance Project Data in Rajasthan. Indian J Pediatr 2002; 69: 667-673.
16. Lee LH, Wenner HA, Rosen L. Prevention of poliomyelitis in Singapore by live vaccine. BMJ 1964; 1: 4077-4080.
17. Poliomyelitis Commission, Western Region Ministry of Health, Nigeria. Poliomyelitis vaccination in Ibadan, Nigeria during 1964 with oral vaccine. Bull WHO 1966; 34: 865-876.
18. Drozodov SG, Cockburn WC. The state of poliomyelitis in the World. In: Proceedings of the 1st international conference on vaccines against Viral and Rickettsial diseases in Man. Washington, DC: Pan American Health Organization; 1969. p. 198-209.
19. Melnick JL. Advantages and disadvantages of killed and live poliomyelitis vaccine. Bull WHO 1978; 56: 21-38.
20. John TJ. Problems with oral polio vaccine in India. Indian Pediatr 1972; 9: 252-256.
21. John TJ, Jayabal P. Oral polio vaccination of children in tropics. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol 1972; 69: 263-269.
22. John TJ. Antibody response of infants in tropics to five doses of oral poliovaccine. BMJ 1976; 1: 811-812.
23. Poland GA, Jacobson RM. The genetic basis for variation in antibody response to vaccines. Curr Opin Pediatr 1998; 10: 208-215.
24. Newport MJ, Goetghebuer T, Weiss HA, Whittle H, Siegrist CA, Marchant A. Genetic regulation of immune responses to vaccines in early life. Genes Immun 2004; 5: 122-129.
25. Grassly NC, Frazer C, Wenger J, Deshpande JM, Sutter RW, Heymann DL, et al. New strategies for elimination of polio from India. Science 2006; 314: 1150-1153.
26. Rota JS, Heath JL, Rota PA, King GE, Celma ML, Carabana J, et al. Molecular epidemiology of measles virus: Identification of pathways of transmission and implications for measles elimination. J Infect Dis 1996; 173: 32-37.
27. Rota JS, Wang ZD, Rota PA, Bellini WJ. Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Res 1994; 31: 317-330.
28. Rota JS, Hummel KB, Rota PA, Bellini WJ. Genetic variability of the glycoprotein genes of current wild-type measles isolates. Virology 1992; 188: 135-142.
29. Tamin A, Rota PA, Wang Z, Heath JL, Anderson JL, Bellini WJ. Antigenic analysis of current wild type and vaccine strains of measles virus. J Infect Dis 1994; 170: 795-801.
30. Rota PA, Bloom AE, Vanchiere JA, Bellini WJ. Evolution of the nucleo-protein and matrix genes of wild-type strains of measles virus isolated from recent epidemic. Virology 1994; 198: 724-730.
31. Paul Y. OPV cannot eradicate polio from India: Do we need any further evidence? Vaccine 2008; 26: 2058-2061.